Sign in6 stories
The Israeli pharmaceutical company reported a Regulation D exempt securities offering tied to warrants issued in early September 2026, filed with the SEC on September 10.
SEC filing
Can-Fite BioPharma said patients across both arms of its Namodenoson HCC trial are surviving longer than the study's design assumptions predicted, prompting consideration of an earlier interim analysis.
SEC filing
New mechanistic findings announced August 17, 2026 back the design of an upcoming Phase IIb pancreatic cancer study following prior Phase IIa results.
SEC filing
The company said Namodenoson and Piclidenoson each hold defined regulatory pathways toward possible marketing approval in the US and Europe.
SEC filing
The company filed a study protocol with an Italian children's hospital for the first clinical test of its drug in this rare genetic disease.
SEC filing
An abstract on Namodenoson in advanced pancreatic ductal adenocarcinoma will be presented as a poster, with one second-line patient alive past 18 months.
SEC filing